Trial Profile
A Randomized, Double-blind, Parallel-Controlled Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Pneumococcal 13 valent vaccine conjugate-Beijing-Minhai-Biotechnology (Primary) ; Hib vaccine conjugate-Minhai; Pneumococcal 7-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Pharmacodynamics; Registrational
- 24 Oct 2021 Results assessing safety and immunogenicity of MINHAI PCV13 in Chinese children aged from 7 months to 5 years old published in the Vaccine
- 11 May 2020 Status changed from active, no longer recruiting to completed.
- 17 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Aug 2018.